ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

Contributed by: Business Wire

Logo

Images

Alamar Biosciences logo (Graphic: Business Wire)

ADx NeuroSciences logo (Graphic: Business Wire)

Business Wire embedded0

Tags

Research

Neurology

Clinical Trials

Biotechnology

Health

Pharmaceutical

General Health

Other Science

Science

Partnership

More Like This

PR Newswire associated0

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

PR Newswire associated0

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.

PR Newswire associated0

Alamar Biosciences launches the NULISAqpcr™ Custom Assay Development Kit to advance the development of novel biomarker assays for clinical research

PR Newswire associated0

Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)

PR Newswire associated0

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

GlobeNewswire associated0

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

PR Newswire associated0

Alamar Biosciences joins forces with SciLifeLab to advance understanding of human disease